Navigation Links
Andrew Powell Joins InterMune As Executive Vice President And General Counsel
Date:9/24/2013

BRISBANE, Calif., Sept. 24, 2013 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced that Andrew Powell has joined InterMune as Executive Vice President, General Counsel and Corporate Secretary.

(Logo:  http://photos.prnewswire.com/prnh/20120827/SF62570LOGO)

Mr. Powell will be responsible for managing the company's legal affairs.  He will report to Dan Welch, Chairman, Chief Executive Officer and President of InterMune.

Mr. Welch said, "Andrew brings experience in many areas that are key to InterMune's future as our Esbriet sales continue to grow globally, and we plan for anticipated approval and launch of Esbriet in the United States."

Mr. Powell's experience spans two decades of leadership in the life sciences, most recently as Executive Vice President, General Counsel and Secretary at Cornerstone Therapeutics. Mr. Powell has practiced law for more than 25 years, principally in healthcare and biotechnology.  He held positions of increasing responsibility for more than 15 years at the multi-national healthcare company Baxter, where he was instrumental in a series of transactions that established Baxter throughout Asia; Mr. Powell led the global law practice at Baxter Bioscience. Subsequently, he was part of the senior team that repositioned Collagenex Pharmaceuticals as a leader in dermatology.  Mr. Powell then served as SVP and General Counsel at ImClone Systems, where he helped the company grow before playing a key role in a successful process that resulted in a sale to Eli Lilly.

Mr. Powell holds a B.A. from the University of North Carolina at Chapel Hill and a J.D. from Stanford Law School.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases.  In pulmonology, InterMune is focused on therapies for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease.  Pirfenidone, the only medicine approved  for IPF anywhere in the world, is approved for marketing by InterMune in the EU and Canada as Esbriet® and is currently in a Phase 3 clinical trial to support regulatory registration in the United States.  InterMune's research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases.  For additional information about InterMune and its R&D pipeline, please visit http://www.intermune.com/.


'/>"/>
SOURCE InterMune, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Insmed Appoints 15-Year Life Sciences Industry Veteran Andrew Drechsler as Chief Financial Officer
2. Eppendorf Video Features Dr Andrew Holts Work on Bioactive Leachates From Plastic Consumables
3. Green Dot Holdings LLC CEO, Mark Remmert, Joins Industry Thought Leaders to Discuss Holistic Sustainable Design at A Better World by Design Conference
4. Robert Tungatt, Regulatory Compliance and Cold Chain Excellence Specialist Joins QuickSTAT
5. Chinese Leader in Genomics Joins Science Center's Port Community
6. Greg Plum Joins the SoundConnect Team
7. Former Life Technologies and BD Biosciences Executive John L. "Kip" Miller Joins Solulinks Board of Directors
8. Dik Barsamian Joins the US HealthConnect Inc. Group of Companies as the New President of Its CME Enterprises
9. Denis Connaghan Joins Clinverse, Inc. as Chief Executive Officer
10. Jeffrey Toobin Joins Gateway Public Schools for the 2013 Matters of the Mind Luncheon
11. Former Head of UK Medicines & Healthcare Products Regulatory Agency (MHRA) Sir Alasdair Breckenridge Joins NDA Partners
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... , March 24, 2017 Agenus Inc. (NASDAQ: ... checkpoint antibodies and cancer vaccines, today announced participation at ... th  Annual William Blair and Maidstone Life Sciences conference ... Center in New York, NY . ... March 29 at 9:40 am: Robert B. Stein ...
(Date:3/23/2017)... ... 23, 2017 , ... Lajollacooks4u is proud to announce it has become the premiere team-building cooking ... for companies around the world, such as Illumina, HP and Qualcomm, and is ranked #1 ... increasing popularity is due to its new team building format, a way for teams to ...
(Date:3/23/2017)...  Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio), a ... solid tumor cancers, today announced that yesterday it ... last Friday, March 17, 2017. ... totaling 28,843,692 shares, comprised of 18,843,692 common shares ... Class C Warrants pre-funded at the closing at ...
(Date:3/23/2017)...  GlobeImmune, Inc. today announced it has entered into ... shares of its common stock to NantCell, Inc., a ... the sale of its common stock, NantCell has agreed ... GlobeImmune 200,000 shares, an estimated $2.0 million in value, ... pleased to enter into this strategic agreement with NantCell," ...
Breaking Biology Technology:
(Date:3/2/2017)... Summary This report provides all ... and its partnering interests and activities since 2010. ... The Partnering Deals and Alliance since 2010 report provides ... of the world,s leading life sciences companies. ... ensure inclusion of the most up to date deal ...
(Date:2/28/2017)... , February 28, 2017 News solutions ... ... Amsterdam from 14 to 16 March, Materna will ... and show how seamless travel is a real benefit for passengers. ... added biometrics to their passenger touch point solutions to take passengers ...
(Date:2/22/2017)... 22, 2017 With the biometrics market ... identifies four technologies that innovative and agile startups ... share in the changing competitive landscape: multifactor authentication ...   "Companies can no longer afford ... says Dimitrios Pavlakis , Industry Analyst at ...
Breaking Biology News(10 mins):